Cronos Group Subject Of SEC Inquiry

This evening, MarketWatch reporter Max Cherney broke the story that Cronos Group (TSX: CRON) (NASDAQ: CRON) has received inquiries from that of the Securities and Exchange Commission related to its revenue recognition practices. The news follows internal investigations conducted by the issuer itself related to certain revenues that were recognized throughout 2019.

As per the report, Cronos staff has been instructed to retain certain documents related to the “confidential and nonpublic inquiry” by the SEC, which is focused on the bulk-resin purchases and biomass wholesale transaction that the company itself is currently reviewing. In a report earlier this week, Cronos revealed that the forensic review of these transactions has resulted in the decrease of 2019 revenues by at least $7.6 million. Associated financial statements filed throughout 2019 will also need to be refiled as a result.

Documents related to the inquiry allegedly require Cronos to keep records that involve a number of public companies that Cronos has transacted and dealt with since June 2018 for various purposes. Those companies include Medipharm Labs (TSX: LABS), Heritage Cannabis (CSE: CANN), TerrAscend Corp (CSE: TER), and 48North Cannabis (TSXV: NRTH).

Silver47 Exploration Inc. — sponsored Sponsored · Silver47 Exploration Inc.

Cronos Group last traded at $5.87 on the Nasdaq.


Information for this analysis was found via Sedar, MarketWatch and Cronos Group. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Majestic Hits 4.24 g/t Gold Over 48.8 Metres at Saval as Jerritt Canyon Restart Advances

First Majestic Lifts Q3 Revenue 38% to US$394.1 Million on Higher Silver Prices

Related News

Medipharm Labs and Cronos Group Sign Second Manufacturing Agreement

Medipharm Labs (TSX: LABS) and Cronos Group (TSX: CRON) (NASDAQ: CRON) have entered into their...

Thursday, September 19, 2019, 09:23:17 AM

Heritage Cannabis Sees Sharples Step Down As CEO, Appointed Chair

Heritage Cannabis (CSE: CANN) has seen a management shakeup occur this morning. The company has...

Wednesday, August 4, 2021, 09:22:38 AM

SEC Charges Cronos Group With Accounting Fraud

Canadian cannabis company Cronos Group Inc (TSX: CRON) and its former senior executive were charged...

Monday, October 24, 2022, 05:52:17 PM

Medipharm Labs Signs White Label Arrangement With Shelter Brand House

Medipharm Labs (TSX: LABS) announced a white labeling agreement with that of 1193269 B.C. Ltd....

Thursday, January 9, 2020, 08:54:10 AM

Medipharm Labs Announces White Label Agreement, Provides No Details

Medipharm Labs (TSX: LABS) has entered into its second white label supply agreement with its...

Monday, May 4, 2020, 08:24:41 AM